These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 17113983)

  • 21. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new era of testosterone and prostate cancer: from physiology to clinical implications.
    Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
    Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testosterone therapy and prostate cancer--safety concerns are well founded.
    Klotz L
    Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer.
    Baillargeon J; Kuo YF; Fang X; Shahinian VB
    J Urol; 2015 Dec; 194(6):1612-6. PubMed ID: 26066403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
    Feneley MR; Carruthers M
    J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of androgen supplementation therapy on the prostate.
    Kaufman JM
    Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring androgen replacement therapy: testosterone and prostate safety.
    Morales A
    J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgens and prostate cancer risk.
    Wirén S; Stattin P
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):601-13. PubMed ID: 18971121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone and prostate cancer: revisiting old paradigms.
    Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
    Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
    Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
    BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone supplementation: what and how to give.
    Jockenhövel F
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.